VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,472,157 | -10.7% | 499,650 | -12.5% | 2.35% | -25.9% |
| Q2 2023 | $28,528,225 | +100.2% | 571,250 | +50.2% | 3.17% | +114.8% |
| Q1 2023 | $14,251,770 | -23.4% | 380,250 | -2.0% | 1.48% | -44.7% |
| Q4 2022 | $18,602,203 | +130.9% | 387,950 | +15.6% | 2.67% | +143.7% |
| Q3 2022 | $8,056,000 | -0.1% | 335,650 | -9.4% | 1.10% | -13.0% |
| Q2 2022 | $8,065,000 | +1.7% | 370,650 | +12.9% | 1.26% | +23.0% |
| Q1 2022 | $7,930,000 | +13.1% | 328,350 | +11.4% | 1.02% | +45.7% |
| Q4 2021 | $7,012,000 | -22.3% | 294,750 | -17.1% | 0.70% | -50.1% |
| Q3 2021 | $9,023,000 | +6.7% | 355,650 | -5.3% | 1.41% | +8.2% |
| Q2 2021 | $8,456,000 | +45.8% | 375,650 | +27.9% | 1.30% | +24.4% |
| Q1 2021 | $5,800,000 | – | 293,650 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |